此外，集团2025财年经调整溢利（非国际财务报告准则计量）（不包括一次性上市相关专业费用）为 2690万美元，年下跌为22.0%。该下跌主要由于Innococo上述暂时性运营困难及外汇影响导致毛利率下 降，以及对Innococo作出战略性营销投资（包括委任新品牌代言人及推出产品促销活动）。 （企业公告） (编辑：王璨 林辰) 2月26日，IFBH发布公告称，2025财年，集团录得总收益1.764亿美元，年增长为11.9%。该增长主要由 if品牌的强劲表现带动，其全年收益增长27%，增幅远超行业平均水平。 公告还提到，尽管if品牌保持强劲增长势头，Innococo全年业绩则受到重大影响，年度下跌63%。业绩 不理想主要归因于营运因素，而非产品需求问题。Innococo遭遇分销商内部问题，以及新运动饮料推出 延误，相关影响在下半年最为显著，期间Innococo收益下跌超过90%。集团已果断采取纠正措施解决有 关问题，并有信心Innococo将于来年重回增长轨道。 ...

Core Viewpoint - The article highlights the strong performance of IFBH, a well-known consumer company, in the recent IPO market, with a significant increase in its stock price, while the other two companies, Taide Pharmaceutical and Yunzhisheng, showed modest performance [1][21]. Group 1: IFBH Performance - IFBH's stock price surged over 60% in the dark market, making it the biggest winner among the three newly listed companies [1]. - The company achieved a subscription multiple of 2240 times, with a financing subscription amount reaching 2594.8 billion HKD [3][11]. - IFBH has a market share of approximately 34% in the coconut water beverage market in mainland China, leading the market for five consecutive years [12][16]. Group 2: Company Overview - IFBH, founded in 2013, specializes in ready-to-drink beverages and ready-to-eat foods, particularly coconut water, and is a leader in the Chinese market [11]. - The company operates on a light asset model, relying on third-party manufacturers for production, with only 46 employees as of the end of 2024 [12][13]. - IFBH's gross profit margin improved from 34.7% in 2023 to 36.7% in 2024, and its net profit margin increased from 19.2% to 21.1% during the same period [16][17]. Group 3: Competitors' Performance - Taide Pharmaceutical, a global leader in peptide-focused CRDMO, holds a market share of 1.5% and provides comprehensive services from early discovery to commercial production [21]. - Yunzhisheng, an AI solutions provider, ranks as the fourth largest AI solution provider in China with a market share of 0.6%, focusing on conversational AI products for daily life and medical applications [22][23]. - Both Taide Pharmaceutical and Yunzhisheng exhibited lackluster performance in the dark market, contrasting sharply with IFBH's success [1][21].